You are here

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

 

Online download statistics by month:

Online download statistics by month: June 2020 to September 2025

AbstractFullPdf
Jun 2020333333146
Jul 202021121160
Aug 202010210068
Sep 202011111154
Oct 202010010072
Nov 2020939359
Dec 2020878729
Jan 202114714774
Feb 202110510532
Mar 202112612656
Apr 202111411441
May 202113613667
Jun 202112612666
Jul 202114014055
Aug 202110910945
Sep 202113713756
Oct 2021154154102
Nov 202116115897
Dec 202112512570
Jan 202210911691
Feb 202210610658
Mar 2022121127115
Apr 202215015676
May 202215015256
Jun 202213513686
Jul 2022919345
Aug 202213613667
Sep 2022959558
Oct 202212713063
Nov 202212212559
Dec 2022959547
Jan 202310310354
Feb 202315215260
Mar 202310610853
Apr 2023777842
May 2023979744
Jun 202311811845
Jul 202311811867
Aug 202313013087
Sep 202311411461
Oct 202311111155
Nov 202314314352
Dec 202314314382
Jan 202412312469
Feb 202414614641
Mar 202416116170
Apr 202411311460
May 202411311461
Jun 2024787952
Jul 2024959653
Aug 2024989840
Sep 202412312366
Oct 202414814945
Nov 202412813075
Dec 202419319796
Jan 202518718991
Feb 202514614656
Mar 202517317481
Apr 202513713762
May 202511411578
Jun 2025757526
Jul 2025110
Sep 2025110
Total781978633894